Zevra Q3 Revenue Jumps 45% to $37.8M as MIPLYFFA Hits $34M; Swings to $19.2M Profit
ZVRA sits 28% above its 52-week low of $8.01.
Summary
Zevra posted Q3 2026 net revenue of $37.8 million, up 45% from $26.1 million a year ago, with $34.0 million of that coming from MIPLYFFA. The company swung to net income of $19.2 million, or $0.31 per basic share, versus a small loss a year earlier, helped by a $5.1 million noncash gain on warrant and CVR fair value adjustments. Cash, equivalents and investments stood at $270.9 million at September 30, and management says that funds the current operating plan. Commercial momentum is steady but not accelerating sharply: 13 new MIPLYFFA prescription enrollment forms in the quarter brought the total to 197 since launch, and 134 patients are enrolled in the global Expanded Access Program. The open items are regulatory — Zevra has requested re-examination of its EU marketing application for arimoclomol and is awaiting the outcome, and it plans to file a supplemental NDA for MIPLYFFA in infants under 24 months in Q1 2027. On celiprolol, the Phase 3 DiSCOVER trial has 72 patients enrolled with four confirmed events, and the company has held an FDA Type C meeting on submission strategy. The 4:30 p.m. ET call today is where guidance and the EU timeline will get pressed.
At the time of this announcement, ZVRA was trading at $10.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.3M. The 52-week trading range was $8.01 to $15.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.